A BREAKTHROUGH ANALGESIC PRODUCT
NOPAYNE™ MINI-EMULSION RANGE
NOPAYNE™ is a proprietary, globally-patented, mini-emulsion 3% lidocaine lipid nanoparticle spray developed by Pharmachal that takes advantage of the company's Nano Drug Delivery System.
Commercial launch is set for 2025, pending successful TGA registration.
Important note: NOPAYNE™ is currently not-for-sale, nor approved for commercial sale. It has not been registered with the Therapeutic Goods Administration. It has, however, been used extensively in humanitarian and compounding environments.
Advantages
A Spray Instead of a Needle
-
No needle preparation, no measuring.
-
Lower patient stress.
-
Sterile through life of product, multi-use, multi-patient spray
Rapid Relief
-
Works within 1 – 2 minutes, directly targeting site of application.
Lower Doses with Better Results
-
Human trials showed that 3% lignocaine NOPAYNE™ works longer than 4% lignocaine Xylocaine™
-
Demonstrated far lower toxicity than competing formulations.
Lower Cost
-
Ingredient costs are comparable to existing products.
-
No needles, syringes or vials provides big cost savings.
-
Multi-use pump allows all NOPAYNE to be used on several patients = no wastage and excellent for emergency situations with multiple casualties.
-
2 year shelf-life reduces wastage.
Safer, Alcohol-free + No Sting
-
No needles = safer handling, safer disposal, less anxious patients.
-
Active ingredients stays at site of application reducing plasma toxicity in cosmetic or procedural surgery and trauma, which could lead to heart failure, a major concern with lidocaine products.
-
Sterile through shelf life.
-
Alcohol-free, no sting
Specialised Pump Spray
-
Accurate dosing every time, No measuring.
-
Double-click action = maintains product sterility and keeps it free from airborne bacteria and microbes.
-
Multiple application on multiple patients.
Poster Presentation
Annual congress of International Federation of Pharmacy on 3rd October 2012, Holland
Download
